GSK buying biopharmaceutical group 35Pharma for $950m
British multinational biopharmaceutical company GSK has reached a definitive agreement to acquire 35Pharma, a Canada-based clinical-stage biopharmaceutical company, for a total cash consideration of $950 million. The deal centres on 35Pharma’s lead asset, HS235, which is a potential best-in-class protein-based therapeutic designed to treat cardiopulmonary diseases. This investigational medicine has successfully completed phase I trials in healthy volunteers and is prepared…